Advertisement

California medical device maker raises $48 million in a Series C financing round in support of research and commercialization of its Senza spinal cord stimulation technology.

Nevro Corp. logo

Menlo Park, Calif.-based Nevro Corp. raised $48 million in a Series C financing round in support of its high-frequency spinal cord stimulation technology, including investments from Covidien (NYSE:COV) Ventures and Johnson & Johnson (NYSE:JNJ) Development Corp.

Nevro develops and markets the Senza HF-SCS system for treatment of chronic pain and other disorders. In July 2012 the company won FDA approval to begin a pivotal trial of the Senza system.

Advertisement
Advertisement